This is the authors' abstract. We don't add key points for this paper.
The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropathy, a devastating complication of the joints that remains poorly understood. The study began recruiting patients in September 2021 and ends in June 2022; the final study results are scheduled for January 2023.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dardari et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: